| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Oncolytics Biotech Inc. | Pelareorep with KEYTRUDA (pembrolizumab) - (NU 18I01) | Pancreatic cancer | Phase 2 | Trial Completed | Intravenous | Oncology |
| Oncopeptides | Pepaxto (melphalan flufenamide) - (OCEAN) | Multiple myeloma | Phase 3 | Intravenous | Oncology | |
| OncoSec Medical Incorporated | TAVO and KEYTRUDA - (KEYNOTE-695) | Melanoma - cancer | Phase 2b | TAVO intratumoral KEYTRUDA intravenous | Oncology | |
| OncoSec Medical Incorporated | TAVO-EP and KEYTRUDA | Neoadjuvant treatment for melanoma | Phase 2 | TAVO-EP intratumoral KEYTRUDA intravenous | Oncology | |
| OncoSec Medical Incorporated | Tavo + OPDIVO (nivolumab) | Neoadjuvant Therapy for Melanoma | Phase 2 | Intratumoral and intravenous | Oncology | |
| OncoSec Medical Incorporated | TAVO + epacadostat + KEYTRUDA (pembrolizumab) - (TRIFECTA) | Head and Neck Squamous Cell Carcinoma | Phase 2 | Intratumoral for TAVO oral for epacadostat intravenous for KEYTRUDA | Oncology | |
| OncoSec Medical Incorporated | TAVO + KEYTRUDA (pembrolizumab) - KEYNOTE-890 | Triple negative breast cancer (TNBC) | Phase 2 | Intratumoral and intravenous | Oncology | |
| OnKure Therapeutics Inc. | Mavodelpar (REN001) - (STRIDE) | Primary mitochondrial myopathies (PMM) | Phase 2b | Trial Discontinued | Oral | Genetic Disorder |